Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525824 · ClinicalTrials.gov registry record · Phase 3
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
A Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,743
- Enrollment target
- 9
- Study locations
NCT00525824 is a Phase 3 study of Atherosclerosis and Hypercholesterolemia that has completed, run by AstraZeneca. The registered enrollment target is 1,743 participants, above the 1,040-participant average among 69 other Atherosclerosis trials with a reported enrollment target (68% higher). The trial reports 9 study locations across 4 states.
The verdict
NCT00525824, a Phase 3 study of Atherosclerosis and Hypercholesterolemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,743 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of \>20%
Conditions Studied
Interventions
- DRUG Simvastatin
- DRUG Ezetimibe
- DRUG Rosuvastatin (Crestor)
Study Locations (9)
Other
- Research Site - Buenos Aires
- Research Site - Santiago
- Research Site - Brentwood
- Research Site - Brentwood
- Research Site - Zwinderen
- Research Site - Brentwood
Tennessee
- Research Site - Brentwood
São Paulo
- Research Site - São Paulo
San Isidro Lima
- Research Site - Lima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,743 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525824
The ClinicalTrials.gov registry entry for NCT00525824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,743 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,040-participant average among 69 other Atherosclerosis trials with a reported enrollment target (68% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which Simvastatin is the first listed.
NCT00525824 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, Tennessee, São Paulo.
Frequently Asked Questions
What is clinical trial NCT00525824 about?
NCT00525824 is a clinical study titled "12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe". The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a C...
What is the current status of trial NCT00525824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,743 participants. The study started on 2007-08. Estimated completion is 2008-09.
What conditions does trial NCT00525824 study?
This clinical trial studies the following conditions: Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease.
What interventions are being tested in trial NCT00525824?
The interventions under investigation include: Simvastatin (DRUG), Ezetimibe (DRUG), Rosuvastatin (Crestor) (DRUG).
Who is sponsoring clinical trial NCT00525824?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525824 being conducted?
This trial has 9 study locations across Tennessee, São Paulo, San Isidro Lima. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
COMPLETED · Phase 3
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.